Drug profile · INN
bacitracin
BACI-RX
bacitracin (BACI-RX) is a c55-isoprenyl pyrophosphate inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — bacitracin
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bacitracin (BACI-RX) is a c55-isoprenyl pyrophosphate inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
C55-isoprenyl pyrophosphate inhibitor
Primary target: C55-isoprenyl pyrophosphate
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is bacitracin?
bacitracin (BACI-RX) is a c55-isoprenyl pyrophosphate inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for bacitracin?
BACI-RX is a marketed brand name for bacitracin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bacitracin?
bacitracin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.